Answers are grounded in this paper and cite their sources.
T hese are exciting times for those committed to pro- viding increased contraceptive choice for men and women.We are still awaiting the discovery of the 'ideal contraceptive', but recent advances will increase contraceptive choice and acceptability of methods. Vaginal ringIn January 2009 NuvaRing was 'quietly' launched in the UK, providing highly effective, monthly contraception for women.This method was fi rst launched in Holland eight years ago and is now used by 1.5 million women worldwide.One vaginal ring (with a diameter of 54mm and a thickness of 4mm) can remain in place for three weeks.This is followed by a 'ring-free' seven days.One of the advantages in delivering hormones vaginally is that lower hormonal doses can be given without compromising contraceptive effi cacy.For example, NuvaRing contains 2.7mg ethinyloestradiol, releasing just 15µg per day, and 11.7mg of etonogestrel, releasing 120µg per day. 1 Even with these low doses, stable hormonal release over a three-week period results in excellent cycle control with less breakthrough bleeding when compared with a number of currently used combined pills. 1 In addition, this method may be useful for those taking broad-spectrum antibiotics, as studies suggest no changes in ethinyloestradiol levels in those taking ampicillin and doxycycline.1
No takes yet. Share an insight, caveat, or question.
Diana Mansour (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: